In Reply We read with interest the letters to the editor concerning our study,1 extending this important debate. The aim of our study was to review all randomized placebo-controlled clinical trials on the effect of anti-inflammatory intervention on depression, depressive symptoms, and adverse effects. The systematic review identified 14 trials, including 6262 patients, and the meta-analysis associated anti-inflammatory treatment with significant antidepressant treatment effect. Nonsteroidal anti-inflammatory drugs (NSAIDs), in particular the selective cyclooxygenase-2 (COX-2) inhibitor celecoxib, showed adjunctive antidepressant effects, whereas results on cytokine inhibitors did not alone reach significance. Thus, the clinical potential of the conducted trials and their results support a proof of concept of anti-inflammatory intervention in depression.